Clinical trials: Keratosis, Actinic
Actinic Keratosis
Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks
Assessment of treatment success and quality of life in patients with actinic keratoses under therapy with Ingenol Mebutate (Picato) in a period of 8 weeks.
- Trial name
- NCT02090465
- Testing
- Ingenol Mebutate
- Where
- Germany
- Volunteers
- 840 people
- Sponsor
- LEO Pharma
Primary Lateral Sclerosis, Adult, 1
"Individual Patient Expanded Access IND to Treat Primary Lateral Sclerosis"
This Individual Patient Expanded Access IND has been created as requested by an 83-year-old man who suffers Primary Lateral Sclerosis and for which the drugs currently approved are not providing an improvement over the…
- Trial name
- NCT04825613
- Testing
- HB-adMSCs
- Where
- United States
- Sponsor
- Hope Biosciences Research Foundation
Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC)
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Organ Transplant Recipients This study is designed to evaluate whether a topical 5% niacinamide cream can help prevent skin cancer in organ…
- Conditions
- Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Actinic Keratosis (AK), Organ Transplant Recipient
- Trial name
- NCT07286318
- Testing
- Topical niacinamide 5% cream, Sunscreen
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Marissa Lobl
Actinic Keratosis
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
The purpose of this study is to prove the safety and efficacy of Levulan Kerastick (aminolevulinic acid HCl) for Topical Solution 20% followed by 10 J/cm2 of blue light delivered at 10 mW/cm2 or 20 mW/cm2 in the treatment of…
- Trial name
- NCT03024060
- Testing
- ALA, Vehicle, IBL 20 mW
- Where
- 7 sites in United States
- Sponsor
- DUSA Pharmaceuticals, Inc.